



● Collect data, explore alternatives ● Advance early R&D ● Bring to market ● Increase uptake Incidence ○ 100M per year

Weighting used for chart

Health Impact – Mortality (50%), Morbidity (20%), AMR (30%).

Prob. of R&D success – Pathogen biology (30%), Pre-clinical and clinical R&D (30%), Pipeline robustness (40%).

Notes: Probability of R&D success (x-axis) was scored by totalling the weighted scorecard scores for each pathogen on: pathogen biology, pre-clinical and clinical R&D and pipeline robustness using the weighting listed below. The range of the combined score is 0-100.

Health impact (y-axis) was scored by totalling the weighted scorecard scores for each pathogen on: mortality, morbidity and urgency of AMR threat using the weighting listed below. The range of the combined score is 0-100.

1) Mortality and morbidity for Haemophilus influenzae B is currently low due to effective vaccine, but would be high without vaccine coverage

2) TB assessment here is of efforts to develop a highly efficacious vaccine.